+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy



The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy



Hpb 15(6): 463-472



Hepatic steatosis, a common condition associated with insulin resistance and excess body weight, is reported to be associated with an increased risk for perioperative mortality in patients undergoing resection of colorectal liver metastases (CLM), but its impact upon longterm survival is less well documented. The effects of background liver pathology, categorized as 'normal', 'with steatosis' and 'other', on perioperative mortality, overall survival (OS) and cancer-specific survival (CSS) were assessed in patients undergoing resection for CLM according to data maintained in the LiverMetSurvey database. As preoperative chemotherapy may confound the effects of steatosis, patients who had been given preoperative chemotherapy were excluded. Survival analyses included log-rank tests for comparisons, and multivariate Cox models, including well-established prognosticators. Of 5853 patients who underwent first-time liver resection without preoperative chemotherapy, 1793 (30.6%) had background steatosis. Rates of 90-day perioperative mortality in patients with normal, steatosis and other pathologies were 2.8%, 2.1% and 4.9%, respectively. Steatosis was associated with improved 5-year OS (47.4% versus 43.0%; log rank, P = 0.0017) and CSS (56.1% versus 50.3%; P = 0.002) compared with normal background liver. After adjustments, the survival advantage associated with steatosis remained (hazard ratio = 0.806, 95% confidence interval 0.717-0.905 for CSS). The paradoxical survival advantage observed in patients with steatosis undergoing liver resection for CLM generates a hypothesis that peri-diagnosis of excess body adiposity has a survival protective effect that warrants further research.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036678456

Download citation: RISBibTeXText

PMID: 23458109

DOI: 10.1111/hpb.12007


Related references

Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. European Journal of Surgical Oncology 40(11): 1436-1444, 2014

Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. Annals of Surgical Oncology 15(6): 1661-1669, 2008

Hepatic resection for colorectal liver metastases influence of survival of preoperative factors and surgery for recurrences in 80 patients. Annals of Surgery 205(3): 256-263, 1987

Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Annals of Surgical Oncology 16(7): 1860-1867, 2009

Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases. Journal of the American College of Surgeons 202(1): 100-111, 2006

Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases. Journal of Hepatology 67(1): 56-64, 2017

Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Annals of Surgery 249(6): 879-886, 2009

Prognostic Value of Hepatic Margin Status After Resection of Colorectal Liver Metastases After Preoperative Chemotherapy. Gastroenterology 146(5): S-1018, 2014

Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM). Journal of Clinical Oncology 23(16_Suppl): 3529-3529, 2016

The Extent of Resection and Insulin-Dependent Diabetes But Neither Preoperative Chemotherapy Nor (Chemotherapy-Induced) Liver Injury Influence Morbidity After Surgery for Hepatic Colorectal Metastases. Gastroenterology 136(5): A-869, 2009

Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Annals of Surgery 246(5): 806-814, 2007

Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. Journal of Surgical Oncology 104(1): 10-16, 2011

Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of Surgical Oncology 17(11): 2870-2876, 2010

Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer. Anticancer Research 36(4): 1949-1954, 2016

Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. European Journal of Surgical Oncology 34(1): 55-60, 2008